0119 Single-Nucleus RNA Sequencing Uncovers Cell Type-Specific Alterations in OSA-Related Liver Injury

Abstract Introduction Chronic intermittent hypoxia (CIH), a hallmark feature of obstructive sleep apnea (OSA), is strongly implicated in the development of hepatic injury. However, the cellular mechanisms underlying CIH-induced liver dysfunction remain poorly understood. This study aimed to systematically characterize the hepatic cellular responses to CIH at single-cell resolution. Methods A rodent model of CIH was established and subjected to histological and transcriptomic analyses. Single-nucleus RNA sequencing (snRNA-seq) was performed to delineate transcriptional alterations across liver cell populations. Differentially expressed genes (DEGs) and pathway enrichment analyses were conducted to identify key biological processes and signaling networks affected by CIH exposure. Results CIH exposure resulted in marked hepatic injury characterized by spotty necrosis and prominent infiltration of inflammatory cells. SnRNA-seq identified ten major hepatocyte clusters with stable composition but revealed extensive transcriptional reprogramming across multiple hepatic subpopulations. CIH suppressed PPAR signaling and fatty acid metabolism in hepatocytes and hepatic stellate cells and activated AMPK and PI3K–Akt pathways related to stress response and fibrogenic processes. Mononuclear phagocytes showed upregulation of NF-κB signaling and complement/coagulation cascades. Endothelial cells exhibited changes in genes associated with cytoskeletal organization and tight junctions. T cell subpopulations displayed altered expression of genes involved in metabolic regulation and endoplasmic reticulum stress. Conclusion This study provides the first single-cell transcriptomic atlas of the liver under CIH, revealing cell type–specific molecular remodeling across hepatocytes, stromal, and immune cells. These findings elucidate the complex cellular interplay driving CIH-induced hepatic injury and offer novel insights into potential therapeutic targets for OSA-related liver dysfunction. Support (if any)